Vertex Pharmaceuticals (VRTX) EBT (2009 - 2026)

Vertex Pharmaceuticals (VRTX) has reported EBT for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT rose 71.54% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $5.2 billion (up 1820.75% YoY), while the FY2025 annual figure was $4.6 billion, up 1768.49% from the prior year.
• EBT came in at $1.3 billion for Q1 2026 at Vertex Pharmaceuticals, down from $1.3 billion in the prior quarter.
• The five-year high for EBT was $1.3 billion in Q4 2025, with the low at -$3.4 billion in Q2 2024.
• Average EBT over 5 years is $868.0 million, with a median of $1.2 billion recorded in 2023.
• Across the five-year window, EBT surged 2417.65% in 2022 and tumbled 391.97% in 2024, its largest moves.
• Year by year, EBT stood at $1.1 billion in 2022, then gained by 6.58% to $1.1 billion in 2023, then fell by 0.97% to $1.1 billion in 2024, then grew by 17.11% to $1.3 billion in 2025, then decreased by 5.87% to $1.3 billion in 2026.
• According to Business Quant data, EBT over the past three periods registered $1.3 billion, $1.3 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.